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This study investigated the antitumour effects of two dual mTOR/PI3K inhibitors, gedatolisib (WYE-
129587/PKI-587/PF-05212384) and PF-04691502 against a panel of six human patient derived ovarian 
cancer xenograft models. Both dual mTOR/PI3K inhibitors demonstrated antitumour activity against 
all xenografts tested. The compounds produced tumour stasis during the treatment period and upon 
cessation of treatment, tumours re-grew. In several models, there was an initial rapid reduction of 
tumour volume over the first week of treatment before tumour stasis. No toxicity was observed during 
treatment. Biomarker studies were conducted in two xenograft models; phospho-S6 (Ser235/236) 
expression (as a readout of mTOR activity) was reduced over the treatment period in the responding 
xenograft but expression increased to control (no treatment) levels on cessation of treatment. 
Phospho-AKT (Ser473) expression (as a readout of PI3K) was inhibited by both drugs but less markedly 
so than phospho-S6 expression. Initial tumour volume reduction on treatment and regrowth rate after 
treatment cessation was associated with phospho-S6/total S6 expression ratio. Both drugs produced 
apoptosis but minimally influenced markers of proliferation (Ki67, phospho-histone H3). These results 
indicate that mTOR/PI3K inhibition can produce broad spectrum tumour growth stasis in ovarian cancer 
xenograft models during continuous chronic treatment and this is associated with apoptosis.
Worldwide, there are approximately 239,000 new cases of ovarian cancer each year accounting for 4% of all 
cancers diagnosed in women1. Standard therapy consists of maximal surgical debulking and 6 cycles of 
platinum-taxane combination chemotherapy. Although most ovarian cancers are initially chemosensitive, the 
majority relapse and ultimately become chemoresistant2,3. Novel therapies are required and since components of 
the phosphoinositide-3-kinase (PI3K) pathway are frequently modified in ovarian cancer, targeting this pathway 
may be beneficial in this disease4–6.
PI3K activates mTOR via AKT and the pathway is activated in 70% of ovarian cancers3. Elevated phospho-Akt 
(Ser473) is found in 68% of ovarian cancers and phospho-mTOR in 55% of tumours7. Constitutive activation 
and deregulation of the PI3K/AKT/mTOR pathway may involve mutational activation or amplification of PI3K 
family members, loss of PTEN function, amplification of the AKT isoenzymes AKT1 and AKT2 or inactivation or 
mutation of AKT-associated mTOR-regulating molecules TSC1 or TSC24–8. In high grade serous ovarian cancer 
(HGSOC), the predominant type of ovarian cancer, it is estimated that the PI3K/AKT/mTOR pathway is activated 
in about half of cancers, with frequent amplifications in PIK3CA, AKT1, AKT2 and deletions in PTEN while 
mutations in the pathways components are relatively uncommon (<5% cancers)4–6,8. By contrast, in non-HGSOC 
e.g. clear cell or endometrioid subtypes, mutational activation is much more frequent and present in up to 30% 
of cancers4–6.
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Multiple inhibitors of the PI3K pathway have been developed and are under consideration for use in ovar-
ian cancer4–6,9. They include PI3K/AKT inhibitors, mTOR inhibitors, and dual PI3K/mTOR inhibitors. This last 
group were developed after demonstration that due to the existence of an S6K1-based negative feedback loop, 
prolonged mTOR inhibition leads to enhanced PI3K/AKT activation10–13. This could be overcome by use of inhib-
itors that simultaneously target both PI3K and mTOR. Two such inhibitors are PF-0469150214,15 and gedatolisib 
(also known as PF-05212384, WYE-129587or PKI-587)16. PF-04691502 has shown interesting activity against 
a large panel of ovarian cancer cell lines in vitro17. Both compounds have now entered Phase I clinical trials18,19.
The purpose of this study was to assess the antitumour efficacy of these two dual mTOR/PI3K inhibitors in 
patient derived xenograft models of ovarian cancer. Use of a panel of xenografts allowed assessment of the varia-
tion of any effects and characterization of the linkage between antitumour response and signalling. Markers of cell 
signalling and function were measured to provide support that the pathway was being inhibited and to provide 
information on the functional consequences.
Results
Assessment of the antitumour activity of Gedatolisib and PF-04691502 against a panel of xen-
ograft models. A panel of six human ovarian cancer xenografts (OV1002, HOX 424, HOX 516, HOX 552, 
HOX 299, HOX 493) were used in this study and four of these (HOX424, OV1002, HOX 516, HOX 493) have 
been described previously20–22. OV1002, HOX 516 and HOX 552 were derived from HGSOC, HOX 424 was 
derived from an endometrioid ovarian cancer while HOX 552 and HOX493 were of clear cell origin.
The two mTOR/PI3K inhibitors, Gedatolisib (1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phe-
nyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea) and PF-04691502 (2-Amino-8-[trans-4-
(2-hydroxyethoxy) cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d] pyrimidin-7(8 H)-one), were 
first assessed against the HOX 552 ovarian cancer xenograft model. PF-04691502 (10 mg/kg/day) was adminis-
tered p.o. over 4 weeks (days 0–4; 7–11; 14–18; 21–25) while gedatolisib (25 mg/kg) was given i.v. on days 0, 4 and 
8 only. Both drugs produced a growth delay during the treatment period with PF-04691502 producing a longer 
lasting effect than gedatolisib (Fig. 1). On discontinuation of either drug, the treated tumours regrew.
A further four xenografts (OV1002, HOX516, HOX299, HOX424) were then tested using the same schedule 
for PF-04691502 but extending the schedule for gedatolisib (days 0, 4, 7, 11, 14, 18, 21 and 25) (Fig. 1). A sixth 
xenograft, HOX 493, was treated with PF-04691502 only (Fig. 1). Using this extended schedule for gedatolisib 
resulted in activity comparable to that of PF-04691502 in the OV1002, HOX516 and HOX299 xenograft models. 
For OV1002 and HOX299, there was an initial decrease in tumour volume during the first 3 days of treatment 
with PF-04691502 which then stabilized over the treatment period. This initial decrease was less obvious for geda-
tolisib. On cessation of treatment, tumours regrew. For the HOX 516 xenograft there was no evidence of an initial 
decrease in tumour volume but significant tumour stasis was achieved while treatment was given. For the HOX 
424 xenograft, both drugs had significant activity against this model, however the gedatolisib-treated tumours 
showed some increase in growth during drug treatment which contrasted with the other models tested. There was 
no significant change in mean body weight of the animals during drug treatment (Supplementary Fig. 1) or any 
other indication of toxicity in these experiments.
In summary, both PF-04691502 and gedatolisib were active against all models tested. A broadly similar 
response was achieved in all cases with consistent static inhibition of tumour growth across all models and 
reduced activity of gedatolisib against the HOX 424 model. In some models, there was evidence of an initial 
reduction in growth over the first 3–7 days but in all cases, this converted to a static effect.
Effects of Gedatolisib and PF-04691502 on PI3K/mTOR signalling in the xenograft models. 
Two xenograft models were then used to study pharmacodynamic changes within tumours. The OV1002 model 
was selected as it had shown marked sensitivity to both dual inhibitors while HOX424 showed reduced sensitivity 
to gedatolisib hence might demonstrate differential effects. Tumours were treated with the same schedule as used 
previously with the addition of two further oral injections for PF-04691502 on Days 28 and 29 and an extra i.v. 
injection for gedatolisib on Day 29. The tumour volume changes on treatment for this experiment are shown in 
Supplementary Fig. 2. Tumours were collected 4 h after injection on days 4, 7 and 29. Tumours were also collected 
on Day 46, 17 days after the last injection when tumours were regrowing. Untreated control tumours were col-
lected on days 0 and 29. As with the antitumour studies, there was no change in mean body weight of the treated 
animals (Supplementary Fig. 3).
To analyse protein expression of selected markers within these xenografts after treatment, two related 
approaches were used. Tissue microarray (TMA) blocks of the xenografts were prepared and sections from these 
blocks assessed by standard immunohistochemistry (IHC) and by quantitative immunofluorescence (IF) using 
AQUA (automated quantitative analysis) methodologies23. TMA sections were cut and stained with a number 
of antibodies. These included phospho-S6 (pS6) and total S6 to evaluate mTOR inhibition and phospho-AKT 
(pAKT) and total AKT to evaluate PI3K inhibition. Markers of function including Ki67 (proliferation, cycling 
cells), phospho-histone H3 (mitotic cells) and apoptosis (apoptotic bodies) were also assessed.
Treatment with either PF-04691502 or gedatolisib markedly reduced pS6 expression in OV1002 xenografts as 
assessed by either IHC or quantitative IF (Fig. 2). Illustrative examples are shown in Supplementary Figs. 4 and 5 
for each day. The mean values for pS6 expression in OV1002 as detected by IHC or IF after treatment are depicted 
in Fig. 2A,B respectively. Phospho-S6 (pS6) expression was significantly reduced throughout the treatment period 
and returns to control values on discontinuation of treatment. Total S6 expression values as measured by AQUA 
did not decrease significantly relative to Day 0 control values (Supplementary Fig. 6).
For HOX 424 xenografts, the effect of PF-04691502 on HOX 424 as detected by IHC is shown in Fig. 2A. 
PF-04691502 produced a significant reduction in pS6 expression on Day 4 while gedatosilib produced a 
non-significant reduction on Day 7 (Fig. 2A). When pS6 expression was detected by AQUA analysis, it was 
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reduced by PF-04691502 on Day 4 period and on Day 7 for gedatolisib, however these results did not achieve 
significance (Fig. 2B). With both agents, even on treatment, the levels of pS6 expression appeared to increase after 
an initial drop. Total S6 expression values as measured by AQUA again didn’t significantly decrease relative to Day 
0 control values (Supplementary Fig. 6).
The expression of pAKT was more homogeneous than that for pS6 in the OV1002 xenograft model 
(Fig. 3A,B). Illustrative examples after treatment are shown in Fig. 3C,D. Significant reductions in pAKT expres-
sion were observed for PF-04691502 and gedatolisib on Day 4 when assessed by IHC (Fig. 3A). However, this 
reduction was not significant when measured by AQUA in TMA cores (Fig. 3B). Although significant changes 
were not observed in pAKT expression using triplicate cores, an analysis of large numbers of fields (10–30) was 
undertaken for each xenograft section and significant changes were observed in OV1002 for both PF-04691502 
(on days 4 and 7) and gedatolisib on Day 7 (p < 0.05; ANOVA). This analysis did suggest that changes in expres-
sion were occurring but the effects were small and not easily detected. While pAKT was reduced on selected days, 
total Akt expression was not reduced on this analysis (Supplementary Fig. 6).
Effects of Gedatolisib and PF-04691502 on apoptosis and proliferation markers within the xen-
ograft models. Next, the effects of the drugs on indicators of functional change were investigated. To assess 
whether the two agents influenced apoptosis, the number of apoptotic bodies were counted in H&E sections 
using microscopy. Ten high powered fields (x 40) were evaluated for each xenograft and the mean value/single 
field was calculated. The mean of the group+/− S.D. is shown in Fig. 4A. Both drugs produced increases in apop-
tosis in both xenograft models at early time points most notably on days 4 and 7.
Two indicators of proliferation were next measured – Ki67 and phospho-histone H3. Ki67 is expressed during 
G1, S, and G2 phases of cell cycle with a peak during mitosis and an absence in G0 phase24. Phospho-histone H3 
(Ser10) is expressed during mitosis25. Ki67 expression did not change significantly after treatment with either 
drug in OV1002 xenografts (Fig. 4B) while PF-04691502 had a small effect in the HOX424 xenograft, reducing 
Ki67 on day 4 only (Fig. 4B). Phospho-histone H3 (Ser10) was unchanged after treatment in xenografts (Fig. 4C).
Figure 1. Antitumour activity of PF-04691502 and gedatolisib against a panel of human ovarian cancer 
xenografts. Both drugs were evaluated against the HOX 552, OV1002, HOX 516, HOX 299, HOX 424 models. 
PF-04691502 only was tested against the HOX 493 model. PF-04691502 (10 mg/kg/day p.o.) and gedatolisib 
(25 mg/kg/day i.v.) were administered on the days indicated by arrows. PF-04691502 was administered over 4 
weeks (days 0–4; 7–11; 14–18; 21–25) against all 6 models while gedatolisib (25 mg/kg) was given on days 0, 4 
and 8 only to HOX 552 but then extended to days 0, 4, 7, 11, 14, 18, 21 and 25 for OV1002, HOX516, HOX299, 
HOX424. Mean (+/− S.E.) tumour volumes are shown. For OV1002 and HOX 299, all treatment points shown 
were statistically different from control (ANOVA followed by Tukey post-test; *p < 0.05). For HOX 516, all 
treatment points beyond Day 3 were statistically different from control. For HOX 552, all treatment points were 
statistically different from control beyond Day 10 until Day 36 for gedatolisib and Day 71 for PF-04691502. For 
HOX424, all treatment points after Day 7 and before Day 35 were statistically different from control. For HOX 
493, all treatment points were statistically different from control until Day 31.
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These results suggest that induction of apoptosis rather than inhibition of proliferation is predominantly 
responsible for the initial tumour volume reduction and stasis.
Association of Gedatolisib and PF-04691502 on pS6/S6 and pAKT/AKT ratios across the xeno-
graft models. We then analysed pS6 and pAKT to assess whether the level of expression of phospho-activated 
molecules might be associated with size of response to drug. Since this comparison was now between different 
xenograft models as opposed to the time course studies which are within individual models, phospho-activated 
expression was compared to the level of total expression (Fig. 5A,B). An association (p = 0.033 (Spearman)) 
was observed (Fig. 5C) between pS6/total S6 expression and tumour volume index (Day 7) after treatment with 
PF-04691502 suggesting that a higher level of initial pS6 expression was associated with a greater initial response 
on treatment.
Analysis of the growth rate of tumours after cessation of treatment also indicated interesting differences in the 
panel of xenografts. The mean doubling times of xenografts after the cessation of treatment with PF-04691502 was 
analysed (from Day 28 onwards) and compared with the initial mean doubling time of the control group (from 
Day 0) (Supplementary Table 1). These ratios (Supplementary Table 1) were then compared with the ps6/total 
S6 expression ratios and a significant association was again observed (p = 0.033 (Spearman)) (Fig. 5D). These 
results suggest that a higher ratio of pS6/total S6 expression is indicative of an initially enhanced response to 
PF-04691502 but then on discontinuation of drug, the tumours relapse more rapidly.
Discussion
The data obtained with the two dual mTOR/PI3K inhibitors indicated broad spectrum activity against these pre-
clinical models of ovarian cancer. The drugs produced a predominantly static effect against the xenograft models 
though in some cases there was an initial tumour volume reduction. In most models, the inhibitory effects ceased 
relatively quickly on cessation of drug treatment. There was no obvious toxicity as indicated by little or no body 
weight loss (Supplementary Fig. 1). The similarities in activity between the two drugs is consistent with both 
drugs having the same mechanism of action. Further work is needed to assess how long stable disease can be 
maintained on continuous drug treatment or whether resistance will emerge.
Figure 2. Expression of pS6 in OV1002 and HOX424 xenografts after treatment with PF-04691502 and 
gedatolisib. (A) pS6 (Ser235/236) expression detected by immunohistochemistry. Immunoscores are shown. 
(B) pS6 (Ser235/236) expression detected by immunofluorescence. Normalised AQUA scores are shown. 
(C) Examples of pS6 (Ser235/236) immunostaining in TMA cores. (D) Examples of pS6 (Ser235/236) 
immunofluorescence staining in TMA cores. Mean values shown are average values +/− S.D. for each group of 
xenografts. *P < 0.05 shown for ANOVA followed by Tukey post-test.
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The biomarker studies completed to date suggest possible utility of pS6 as an indicator of response in tumour 
biopsies. A previous in vitro study evaluating PF-04691502 against 33 ovarian cancer cell lines in vitro concluded 
that sensitivity to the drug did not correlate with PI3 kinase activating mutations or PTEN loss in this disease17. 
Our analysis suggests early inhibition of mTOR signalling as indicated by reduction of pS6 expression but perhaps 
only short term control of pAKT expression. The inhibition of both pathways leads to an early decrease in tumour 
volume in some models but this appears to convert to stasis if only mTOR inhibition is sustained. Increased apop-
tosis rather than reduced proliferation was associated with growth stasis. Previous in vitro studies using ovarian 
cancer cell lines have associated mTOR inhibition with increased apoptosis26. In breast cancer cell line models, 
greater growth inhibition was observed in luminal and HER2-positive cell lines than in triple-negative cell lines 
after treatment with PF-04691502, with apoptosis being observed in the former27.
The initial tumour volume inhibition appeared to be strongest where pS6/total S6 expression was highest 
suggesting that tumours with the greatest pathway activation might be inhibited more. Similarly, on cessation 
of treatment, the xenografts regrew most rapidly where this ratio was greatest again supporting dependency on 
this pathway. This data supports the possible use of the pS6/total S6 ratio as a potential biomarker to help predict 
response but also potential rapid regrowth if the drug is stopped; this will require further validation.
On the basis of these results, these dual inhibitors have broad spectrum activity against ovarian cancer models 
producing disease stabilization rather than disease response (although some models did show an initial partial 
response). This could be valuable in extending time to progression when used as a maintenance therapy following 
chemotherapy. Both HGSOC and non-HGSOC xenografts responded to this treatment, which is not unexpected 
as these pathways are activated in multiple histological subtypes of ovarian cancer. The inhibitors were active 
when given continuously and cessation of treatment led to tumour regrowth. In these in vivo models in mice, 
disease stabilization was produced at doses that did not appear to have obvious toxicity.
These xenograft models may be of value in helping to define further the dynamic changes occurring on treat-
ment. It is possible that feedback mechanisms are limiting the pAKT inhibition and further studies might identify 
these pathways within this xenograft material. If this were the case, use of other targeted inhibitors in conjunction 
with the mTOR/PI3K inhibitors might produce more potent antitumour effects.
Both PF-04691502 and Gedatolisib (PF-05212384) have now progressed through Phase I clinical trials18,19 
and are being studied in combination with chemotherapy and inhibitors of other targeted pathways28. Within the 
Figure 3. Expression of pAKT (Ser473) in OV1002 and HOX424 xenografts after treatment with PF-
04691502 and gedatolisib. (A) pAKT (Ser473) expression detected by immunohistochemistry. Immunoscores 
are shown. (B) pAKT (Ser473) expression detected by immunofluorescence. Normalised AQUA scores are 
shown. (C) Examples of pAKT (Ser473) immunostaining in TMA cores. (D) Examples of pAKT (Ser473) 
immunofluorescence staining in TMA cores. Mean values shown are average values +/− S.D. for each group of 
xenografts. *P < 0.05 shown for ANOVA followed by Tukey post-test.
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phase I trial for PF-04691502, no responses were reported but stable disease was observed in 33% of patients18. 
Fatigue and rash were dose-limiting. A partial blockade of p-AKT (Ser473) signalling was observed in a group 
of 5 pre- and post-treatment biopsies18. In the Phase I trial of Gedatolisib, two partial responses (2.6%) were 
observed and disease stabilisation in 35% of patients. Comparison of tumour biopsies indicated a mean 30% 
reduction if p-AKT (Ser473) in a series of 8 pre-/post-treatment biopsies19. Our results indicate that it would be 
worthwhile evaluating changes in pS6 expression also in future studies with these drugs.
A multi-arm Phase I study which investigated both drugs in combination with either irinotecan or the 
MEK inhibitor PD-0325901 reported preliminary evidence of activity of gedatolisib plus the MEK inhibitor 
PD-0325901 in 3 ovarian cancer patients (all partial responses) out of 5 tested28. In cell line xenograft models 
(SKOV3 and A2780) of ovarian cancer, gedatolisib has shown enhanced antitumour activity when combined with 
crizotinib (a c-Met inhibitor) although its single agent activity was very limited29.
In conclusion, these results support continued consideration of these inhibitors for use in ovarian cancer.
Methods
Xenograft studies. The xenografts had been previously established in adult female CD-1 nude mice (housed 
in sterile isolators) directly from clinical material (ascites) and then passaged a minimum number of times until 
growth was reproducible and sufficient material was available to undertake experiments (4–10 passages). For 
the experiments described, groups of mice were implanted with fragments, subcutaneously in each flank. Group 
size was a minimum of 6 mice/group with at least 8 tumours/group. Tumours were allowed to grow to a group 
mean size of greater than 100 mm3 before drug treatment was initiated. PF-04691502 (2-Amino-8-[trans-4-
(2-hydroxyethoxy) cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido [2,3-d] pyrimidin-7(8 H)-one 
was prepared as a suspension in 0.5% carboxymethylcellulose (CMC) in sterile distilled water. Gedatolisib 
(1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phe-
nyl]urea) was prepared as a suspension in 4% ethanol, 2% Tween and 4% PEG 400 in distilled water. In the 
initial experiment using HOX552, PF-04691502 (10 mg/kg/day) was administered by oral gavage over 4 weeks 
(days 0–4; 7–11; 14–18; 21–25) while gedatolisib (25 mg/kg/day) was given intravenously in the tail vein on 
days 0, 4 and 8 only. In the subsequent experiments, gedatolisib was administered on days 0, 4, 7, 11, 14, 18, 21 
and 25. Tumour volumes were measured on the days shown in the figures using vernier calipers and calculated 
as volume = π/6 × l × w2 where l is the length of the tumour and w = width. In a separate experiment, a time 
course study over the drug treatment period was undertaken and tumours collected at the time points indicated. 
Tumours were collected 4 h after injection on the day described. Samples were placed into formalin as fixative 
and were subsequently embedded (FFPE) into paraffin wax. The xenograft studies were undertaken under a UK 
Home Office Project Licence in accordance with the Animals (Scientific Procedures) Act 1986 and studies were 
approved by the University of Edinburgh Animal Ethics Committee.
Figure 4. Apoptosis, Ki67 and phospho-histone H3 expression in OV1002 and HOX 424 xenografts after 
treatment with PF-04691502 and gedatolisib. (A) Mean number of apoptotic bodies in a high-field (x 40) view 
for OV1002 xenografts and HOX 424 xenografts. Mean values shown are average values for each group of 
xenografts. Ten fields were evaluated for each individual xenograft and the mean value was evaluated. (B) Ki67 
expression. Mean % Ki67 expression is shown. C. Phospho-histone H3 expression. Mean % value (+/− S.D.) is 
shown for each group. *P < 0.05 shown for ANOVA followed by Tukey post-test.
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Tissue microarray preparation and immunohistochemistry studies. For analysis of protein expres-
sion, three replicate tissue microarrays (TMAs) were prepared which used triplicate cores from each of the xeno-
grafts in the study. Sections were then cut from these TMA blocks.
A standard Envision immunohistochemistry protocol was used to assess proteins of interest23. Briefly, sections 
were de-waxed in xylene followed by rehydration. Antigen retrieval was undertaken in a sodium citrate buffer 
pH 6.0 for 10 min. Slides were placed into distilled water, then washed in PBST twice for 5 min. Sections were 
placed into 3% H2O2 for 10 min, then washed 3 times with PBST. Sections were added to Sequenza and washed 
with PBST. These were blocked with DAKO total protein block for 10 min. Primary antibody was diluted with 
DAKO antibody diluent and sections incubated in primary antibody either for an hour at room temperature or 
overnight at 4 °C. The following rabbit primary antibodies were used at the stated dilution; pS6 (Ser235/236) 
(Cell Signalling #2211) (1 in 200); S6 (Cell Signalling #2217) (1 in 100); pAKT (Ser473) (Cell Signalling #4060) 
(1 in 100) and AKT (pan) (Cell Signalling #4685) (1 in 200). Sections were washed 3 times with PBST, followed 
by incubation with DAKO Envision labeled polymer for 30 min at room temperature. Slides were washed 3 times 
with PBST. DAB (DAB substrate: DAB chromagen = 1 ml: 20ul) was added to visualize staining. Sections were 
washed in water and counterstained in hematoxylin (15–20 sec) followed by Scot’s tap water for 15–20 sec. Slides 
were dehydrated 2 min: 50%, 80%, 99%, 99% alcohol and then mounted. Expression was measured by a scoring 
system consisting of the product of the percentage of positively stained tumour cells and intensity of staining 
(0–3) producing an immunoscore ranging from 0 to 300. For assessment of apoptotic counts, H&E sections were 
assessed. Ten high field (x 40) areas were counted and the mean value calculated. Apoptotic bodies were identified 
as membrane enclosed bodies with condensed/fragmented nuclei and frequently with eosinophilic cytoplasm.
Quantitative immunofluorescence (AQUA) studies. For assessment of protein expression by quan-
titative immunofluorescence, the following protocol was used23. Briefly, TMA sections were de-waxed in xylene 
2 × 5 min. This was followed by rehydration for 2 min in 99%, 99%, 80% and 50% alcohol. Antigen retrieval was 
undertaken in a sodium citrate buffer pH 6.0 where slides were boiled for 5 min. They were washed in PBST 
Figure 5. Association between pS6/total S6 expression and tumour volume index in 6 human ovarian cancer 
xenografts. (A) Baseline pS6, S6, pAKT and AKT mean values are shown for each xenograft model. (B) Ratios of 
pS6/S6 and pAKT/AKT are shown for each model. (C) Association between pS6/S6 expression plotted against 
tumour volume change after PF-04691502 treatment over 7 days. (D) Association between pS6/S6 expression 
plotted against the ratio of mean tumour volume doubling time (Td) at cessation of PF-04691502 treatment and 
mean tumour volume doubling time of untreated control.
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(PBS/Tween) twice for 5 min. Sections were then placed in 3% H2O2 for 10 min, then washed 3 times with PBST. 
Sections were added to sequenza and washed with PBST. These were blocked with DAKO total protein block for 
10 min. For mouse primary antibody, this was diluted at optimal dilution with second primary antibody (rabbit 
anti-cytokeratin, DAKO, Z0622, 1:150 dilution) diluted in DAKO antibody diluent either for an hour at room 
temperature or overnight at 4 °C. The same primary antibodies for pS6, S6, pAKT and AKT as used for IHC were 
used for immunofluorescence at the same dilutions while phospho-histone H3 (Ser10) (Cell Signalling #9701S) 
was used at 1 in 100 dilution and anti- Ki67 (DAKO M7240) was used at a 1 in 50 dilution. For rabbit primary 
antibody, the same protocol was used except the second primary antibody used was mouse anti-cytokeratin, 
Dako, M3515 diluted in Dako antibody diluent with 1:50 dilution overnight at 4 °C. Epithelial mask visualiza-
tion then required a 1:25 dilution of the goat anti-mouse Alexa555 Ab (Invitrogen, #A21422) in the pre-diluted 
Envision goat-rabbit HRP antibody solution (Dako, #K4003). Sections were washed 3 times with PBST. A 1:25 
dilution of the goat anti-rabbit Alexa555 Ab (Invitrogen, #A21428) in the pre-diluted Envision goat-mouse HRP 
antibody solution (Dako, #K4001) was prepared and added to slides which were then rinsed in 0.05% PBST 
3 × 5 min. Slides were transferred from Sequenza to the humidity chamber. For target visualization, target sig-
nal amplification diluent and the Cy5 Tyramide at 1:50 concentration were combined. These were vortexed to 
mix thoroughly. Slides were incubated with solution in the dark for 10 min at room temperature. Slides were 
washed 3 times with PBST. These were then dehydrated in 80% IMS for 1 min and air dried in the dark. For 
counterstaining and coverslipping, 45ul Prolong Gold anti-fade reagent with DAPI (Invitrogen, P36931), nuclear 
visualisation media, was applied on the coverslip (22 × 40 mm) and the coverslip was placed over the tissue. The 
mounted slide was left to dry overnight in the dark. After slides were completely dried, the coverslips were sealed. 
Monochromatic images of each TMA core were captured at x20 objective using an Olympus AX-51 epifluores-
cence microscope, and high-resolution digital images analysed by the AQUAnalysisTM software23.
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